
---
title: '浙大联合良渚实验室发现癌症免疫治疗新靶点，通过下调 PD-L1 激发自体免疫，成果将通过公司进行转化｜专访'
categories: 
 - 新媒体
 - MIT 科技评论
 - 首页
headimg: 'https://p3.toutiaoimg.com/img/pgc-image/a15255951c6842009039188727858111~tplv-tt-shrink:640:0.image'
author: MIT 科技评论
comments: false
date: Wed, 05 May 2021 11:09:11 GMT
thumbnail: 'https://p3.toutiaoimg.com/img/pgc-image/a15255951c6842009039188727858111~tplv-tt-shrink:640:0.image'
---

<div>   
<p style="line-height: 30px;"><span style="font-size: 18px;">﻿</span><span style="color: rgb(89, 89, 89); letter-spacing: 1px; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;">肿瘤是“机体内某一局部组织细胞的过度增生”，很多人都知道它可以分为良性肿瘤和恶性肿瘤。</span></p><p data-track="2" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="3" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">但肿瘤其实也分冷热，</span><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">学界将有免疫原性、会被自身免疫细胞攻击的肿瘤称为 “热肿瘤”，而无免疫原性、容易逃避免疫系统攻击的称为 “冷肿瘤”。</span></span></span></p><p data-track="4" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="5" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">其中，“冷肿瘤”在接受免疫治疗后往往疗效不佳，一直是医生与患者头痛的难题。</span></span></p><p data-track="6" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="7" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">目前，肿瘤靶向治疗已成为肿瘤研究中的热点，通过对肿瘤特异性靶点的选择性攻击，可以在较少损害正常组织的情况下，针对性地对肿瘤细胞进行攻击。</span></span></p><p data-track="8" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="9" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">近年来，对于某些特定的肿瘤如 EGFR表达阳性的肺癌、Her2 表达阳性的乳腺癌，靶向治疗方法的效果比较出色。</span></span></p><p data-track="10" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="11" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">然而，有一些癌症组织在受体表达上与正常组织相比并没有明显不同，甚至可以通过高表达正常组织具有的免疫信号分子来逃避免疫系统的攻击，比如三阴性乳腺癌。</span></span></p><p data-track="12" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="13" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">许多能逃避免疫系统攻击的肿瘤细胞表面，都具有 PD-1（程序性死亡受体1）蛋白的配体 PD-L1 蛋白，该蛋白也存在于抗原提呈细胞表面；而 PD-1 蛋白则位于活化的 T 细胞表面。PD-L1蛋白通过结合PD-1蛋白抑制 T 细胞的炎症活动，削弱免疫系统对外来侵略的攻击，并促进自身耐受。这避免了自身免疫性疾病的产生，但也导致了癌细胞的免疫逃逸。</span></span></p><p data-track="14" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="15" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">打个比方，肿瘤细胞与 T 细胞好比在打谍战，而 PD-1 与 PD-L1 是暗号，如果肿瘤细胞能在 T 细胞喊出 “PD-1”时对上暗号 “PD-L1” 来证明身份，T 细胞就不会攻击。</span></span></p><p data-track="16" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="17" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">基于肿瘤细胞的这种特性，针对 PD-1 和 PD-L1 的单克隆抗体，已广泛应用于临床的抗肿瘤治疗。</span></span></p><p data-track="18" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="19" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">但对于不同类型的肿瘤，单抗药物的临床反应率不仅不一致、而且普遍较低，甚至已有文献认为目前的 PD-1 抗体治疗，对于三阴性乳腺癌是无效的。此外，昂贵的价格，也给肿瘤患者们带来巨大的经济负担。</span></span></p><p data-track="20" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="21" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">为克服 PD-1/PD-L1 抗体药物的一系列不足之处，浙江大学医学院 / 良渚实验室的夏宏光团队在最新研究中，筛选了一系列调控PD-L1蛋白水平下降的先导化合物，并阐明了 PD-L1 蛋白新的降解机制。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p3.toutiaoimg.com/img/pgc-image/a15255951c6842009039188727858111~tplv-tt-shrink:640:0.image" img_width="543" img_height="329" image_type="1" mime_type="image/webp" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">图 | 夏宏光（来源：受访者）</p></div><p data-track="25" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">他们发现，ARIH1（Ariadne RBR E3 Ubiquitin Protein Ligase 1），是负责靶降解 PD-L1 的 E3 泛素连接酶。</span></span></span></p><p data-track="26" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">他们还发现肿瘤细胞会通过 EGFR-GSK3α-ARIH1 信号传导来逃避免疫系统攻击的机制，并提示 ARIH1 是肿瘤免疫治疗新的潜在药物靶点。</span></span></span></p><p data-track="27" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="28" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">4 月 20 日，相关论文以标题 ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation 发表于 Nature Communications。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p3.toutiaoimg.com/img/pgc-image/5a8c3b049cf44c828433e16ee01de112~tplv-tt-shrink:640:0.image" img_width="1080" img_height="561" image_type="1" mime_type="image/png" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px;"></p></div><p data-track="30" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(136, 136, 136); --tt-darkmode-color: #888888;">图 | 相关论文（来源：受访者）</span></span></p><p data-track="31" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><h1 class="pgc-h-arrow-right" data-track="32" style="margin-bottom: 20px; padding: 0px; border: 0px; position: relative; font-weight: 700; font-size: 1.5em; color: rgb(34, 34, 34); line-height: 1.33333; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif;">高通量筛选确定促进 PD-L1 降解的先导化合物</h1><p class="pgc-p syl-page-br" data-track="122" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="34" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">该团队对 2125 种 FDA 批准的药物及候选药物进行高通量筛选之后，鉴定了 一系列促进PD-L1 降解的先导化合物。</span></span></p><p data-track="35" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="36" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">为了建立一个基于荧光的测定内源性 PD-L1 膜蛋白水平的高通量筛选模型，夏宏光使用了与藻红蛋白（P-phycoerythrin,PE）结合的 PD-L1 抗体和干扰素 -γ（IFNγ）处理的 U937 细胞（组织细胞性淋巴肉瘤细胞系）。</span></span></p><p data-track="37" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="38" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">其中，干扰素 -γ 增强了 PD-L1 的基础表达水平，使得后者的动态范围更广，因而其结果也更具精确性与说服力。</span></span></p><p data-track="39" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="40" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">该团队还发现，在这些 FDA 批准的药物及候选药物中，共有 160 种药物可以降低 PD-L1 膜蛋白水平。</span></span></p><p data-track="41" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="42" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">随后，夏宏光根据这些先导化合物参与的信号通路，对阳性药物进行分类，其中包括 JAK/STAT 通路（The Janus kinase/signal transducer and activator of tran-ions）抑制剂、磷脂酰肌醇 3 - 激酶（PI3K）/蛋白激酶 B/mTOR 通路抑制剂、细胞周期调节激酶抑制剂等，这些都是已知的能对PD-L1膜蛋白水平发挥调控功能的通路抑制剂。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p6.toutiaoimg.com/img/pgc-image/8ba0b3d123d94a0bbc88df6fab0f1537~tplv-tt-shrink:640:0.image" img_width="875" img_height="790" image_type="1" mime_type="image/png" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">图 | 筛选可有效降低PD-L1膜蛋白水平的先导化合物（来源：受访者）</p></div><h1 class="pgc-h-arrow-right" data-track="32" style="margin-bottom: 20px; padding: 0px; border: 0px; position: relative; font-weight: 700; font-size: 1.5em; color: rgb(34, 34, 34); line-height: 1.33333; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif;">锁定研究对象 ——靶向药物 ES-072</h1><p data-track="47" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; white-space: normal; text-align: center;"><br></p><p data-track="48" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">已有大量研究表明，表皮生长因子受体信号通路可激发 PD-L1 表达，并引起肿瘤细胞的免疫逃逸。筛选获得的靶向药物 ES-072 也是表皮生长因子受体抑制剂，是夏宏光参与开发的靶向新药，夏宏光将它定为研究对象。</span></span></p><p data-track="49" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="50" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">为探索靶向药物 ES-072 诱导 PD-L1 降解的背后机制，该团队测试了ES-072 处理后PD-L1是否会发生磷酸化变化，并通过生物质谱等实验证实了 PD-L1 的降解取决于其胞内段 Ser279 和 Ser283 这两个位点的磷酸化。</span></span></span></p><p data-track="51" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="52" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">由于表皮生长因子受体活性丧失会导致蛋白激酶 B 活性下降，而蛋白激酶 B可同时调控糖原合成激酶 - GSK3α 与 GSK3β。</span></span></p><p data-track="53" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="54" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">为搞清楚到底谁起了主要作用，他们进行了大量实验，并利用生物质谱等技术发现了一系列与 PD-L1 相互作用的激酶蛋白。</span></span></p><p data-track="55" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="56" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">其中，ES-072 处理后，GSK3α 与 PD-L1 膜蛋白的相互作用，显著增强（见下图）。</span></span></p><p data-track="57" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p5.toutiaoimg.com/img/pgc-image/24e3e153e95b4a7db8f6cdfb8221a83a~tplv-tt-shrink:640:0.image" img_width="524" img_height="394" image_type="1" mime_type="image/jpeg" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">图 | PD-L1 免疫沉淀后的质谱分析结果（来源：受访者）</p></div><p data-track="61" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">体外磷酸化等并行实验也证明，表皮生长因子受体抑制剂诱导的 PD-L1 Ser279/283 位点磷酸化是由 GSK3α介导的。</span></span></p><p class="pgc-p syl-page-br" data-track="123" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><h1 class="pgc-h-arrow-right" data-track="32" style="margin-bottom: 20px; padding: 0px; border: 0px; position: relative; font-weight: 700; font-size: 1.5em; color: rgb(34, 34, 34); line-height: 1.33333; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif;">E3 泛素连接酶登上舞台</h1><p data-track="63" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="64" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">在理清楚这条通路后，夏宏光又提出了新问题 —— 在使用靶向药物 ES-072 治疗后，究竟是哪个 E3 泛素连接酶促进了 PD-L1 的泛素化和降解呢？</span></span></p><p data-track="65" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="66" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">在分析质谱数据后，他发现</span><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">除了已知的介导 PD-L1 降解的 Cullin 连接酶外，靶向药物 ES-072 还促进了 PD-L1 与名为 ARIH1 的 E3 泛素链接酶的相互作用。同时他还发现，ARIH1 的瞬时过表达，可促进 PD-L1 的 K48 相关泛素化增强。</span></span></span></p><p data-track="67" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="68" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">此外，ARIH1 在人肺腺癌细胞H1975和人胚胎肾细胞 293 中高表达，可“剂量依赖”地促进内源性 PD-L1 降解，而 ARIH1 敲除则导致内源性 PD-L1 水平增加。一系列实验结果表明，ARIH1 能直接泛素化 PD-L1，并介导其通过蛋白酶体降解。</span></span></p><p data-track="69" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="70" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">接下来，夏宏光测试了 GSK3α介导的 PD-L1 在 Ser279/283 位点的磷酸化是否促进了 PD-L1 招募 ARIH1。</span></span></p><p data-track="71" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="72" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">他和团队将稳定表达 ARIH1的人胚胎肾细胞 293，转染上野生型 PD-L1 或耐磷酸化的 S279A、S283A、2SA（S279A 和 S283A 两个位点的合称）突变体。</span></span></p><p data-track="73" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="74" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">结果显示，在 S279A 和 S283A 突变的细胞中，ARIH1 高表达诱导的 PD-L1 泛素化大量减少，与此一致的是，ARIH1 与 PD-L1 的相互作用也因 2SA 突变而显著降低。</span></span></p><p data-track="75" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="76" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">靶向药物 ES-072 的处理，增强了 ARIH1 和野生型 PD-L1 之间的相互作用，但没有增强其和 PD-L1 2SA 突变体的相互作用，而 GSK3α 高表达诱导的 PD-L1 泛素化，则被 ARIH1 的敲除所阻断。</span></span></p><p data-track="77" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="78" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">因此，该团队得出结论，</span><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">GSK3α 驱动PD-L1的 Ser279/283 磷酸化，PD-L1随后招募 ARIH1 并通过 K48 相关泛素链将自身泛素化，并靶向蛋白酶体降解。</span></span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p6.toutiaoimg.com/img/pgc-image/ec0e63b73abd4139a3c950e3b6ef6fed~tplv-tt-shrink:640:0.image" img_width="1188" img_height="1006" image_type="1" mime_type="image/jpeg" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">图 | GSK3α 介导的 PD-L1 的磷酸化促进 PD-L1/ARIH1 相互作用和 ARIH1 诱导的降解 活体实验效果喜人</p></div><p data-track="83" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">在活体实验方面，该团队分别使用 4T1 小鼠乳腺癌细胞、免疫缺陷裸鼠、和野生型正常小鼠，来评估 ARIH1 在调控 PD-L1 降解和肿瘤发生中的作用。</span></span></p><p data-track="84" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="85" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">据悉，当4T1细胞注射到 BALB/c 小鼠（白变种实验室老鼠，即俗称的 “小白鼠 “）中时，小白鼠体内可自发产生高转移性肿瘤，并在注射部位形成原发灶。实验表明，4T1细胞在小白鼠中的生长转移特性与人体中的三阴性乳腺癌非常相似。</span></span></p><p data-track="86" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="87" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">在4T1细胞中高表达 ARIH1，对4T1细胞的体外增殖、以及在免疫缺陷裸鼠的生长并没有影响。但是，在免疫功能正常的小白鼠中，ARIH1高表达肿瘤生长受到了极大的抑制，其中大部分小白鼠的肿瘤完全消退。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p9.toutiaoimg.com/img/pgc-image/3dac8fbea4f249f6bc92b33c0fb46419~tplv-tt-shrink:640:0.image" img_width="863" img_height="357" image_type="1" mime_type="image/png" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">（来源：受访者）</p></div><p data-track="91" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">同时，在 ARIH1 高表达肿瘤微环境中，浸润肿瘤的免疫细胞、活化 CD8 + 细胞、毒性 T 细胞的水平明显增加。并且，ARIH1 高表达还导致炎症细胞因子的表达增加，包括干扰素 -γ、肿瘤坏死因子 -α 、炎性趋化因子 CCL-5 、以及 T 淋巴细胞趋化因子 CXCL-10等。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p3.toutiaoimg.com/img/pgc-image/c6e4b26f6e3f45bda63ce5f30d36ab2b~tplv-tt-shrink:640:0.image" img_width="831" img_height="408" image_type="1" mime_type="image/png" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">（来源：受访者）</p></div><p data-track="95" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">4T1 系小鼠乳腺癌细胞，是逃离免疫系统攻击的癌细胞中的佼佼者，ARIH1 能使免疫系统发生活跃的炎性反应，这说明 ARIH1 在促进肿瘤免疫方面发挥了明显作用，诱导ARIH1高表达的药物在肿瘤免疫疗中的应用前景，非常值得期待。</span></span></p><p data-track="96" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="97" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">那么在人体中，肿瘤细胞也是通过该机制来逃避免疫系统攻击的吗？</span></span></span></p><p data-track="98" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="99" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">对肿瘤和其远端组织样本的免疫组化分析显示， ARIH1 蛋白水平在远端组织中的水平远高于肿瘤组织。</span></span></p><p data-track="100" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="101" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">这一发现与细胞与小鼠实验中 ARIH1 促进 PD-L1 降解的现象是一致的，这说明人体肿瘤细胞中 ARIH1 表达的缺失，是导致肿瘤细胞PD-L1 蛋白累积的机制之一。</span></span></p><p data-track="102" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="103" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">但导致肿瘤中 ARIH1 表达水平下降的机制还有待阐明。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p6.toutiaoimg.com/img/pgc-image/d6b76538c73940678534f04b49b14c7c~tplv-tt-shrink:640:0.image" img_width="752" img_height="474" image_type="1" mime_type="image/jpeg" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px;"></p></div><p data-track="105" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(136, 136, 136); --tt-darkmode-color: #888888;">图 | 经 EGFR-GSK3α-ARIH1 调控的 PD-L1 膜蛋白降解示意图</span></span></p><p data-track="106" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><h1 class="pgc-h-arrow-right" data-track="32" style="margin-bottom: 20px; padding: 0px; border: 0px; position: relative; font-weight: 700; font-size: 1.5em; color: rgb(34, 34, 34); line-height: 1.33333; font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif;">治愈疑难肿瘤未来可期，“冷肿瘤” 变 “热肿瘤”</h1><p data-track="108" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="109" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">考虑到4T1细胞是一种著名的冷肿瘤，PD-1/PD-L1抗体单独使用几乎对4T1肿瘤没有抑制作用，本研究结果还提示，ARIH1不仅可以调控PD-L1降解，而且可以重塑肿瘤微环境，可能是将“冷肿瘤”变成“热肿瘤”的关键分子。夏宏光课题组通过后续的研究已经初步探明ARIH1调控肿瘤“冷”、“热”切换的机制，并开始筛选诱导ARIH1高表达的先导化合物。</span></span></p><p data-track="110" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="111" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">临床上三阴性乳腺癌也是著名的 “冷肿瘤”，PD-1抗体在该适应症上的临床实验已经失败；</span><span style="margin: 0px; padding: 0px; border: 0px; font-weight: 700;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">本研究成果提示，诱导ARIH1表达的药物小分子有望成为治疗包括三阴性乳腺癌在内的一系列“冷肿瘤”的靶向新药。</span></span><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">也就是说，在未来的某一天，治愈三阴性乳腺癌、难治性黑色素瘤、非小细胞肺癌等 “冷肿瘤”将不再是幻想！</span></span></p><p data-track="112" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="113" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">2021 年初，夏宏光已成立公司，他表示本次成果也将在该公司进行转化。夏宏光博士也是良渚实验室研究员，负责“分子筛选与合成平台”与个性化药物筛选。</span></span></p><p data-track="114" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="115" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">良渚实验室是浙江省实验室之一，成立于 2020 年 7 月，定位是“浙江省医学科技策源地，生命健康产业主引擎”。良渚是杭州的一处地名，也是“中华文明的曙光 —— 良渚文化的发祥地”，以“良渚”命名该实验室，足见用意之深远。</span></span></p><div class="pgc-img" style="margin: 0px 0px 18px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px;"><img src="https://p5.toutiaoimg.com/img/pgc-image/8de4b849d796449cae9929f0d8395e2c~tplv-tt-shrink:640:0.image" img_width="1108" img_height="414" image_type="1" mime_type="image/jpeg" class="syl-page-img" style="margin: 0px auto 8px; padding: 0px; max-width: 100%; display: block;" referrerpolicy="no-referrer"><p class="pgc-img-caption" style="margin-bottom: 0px; padding: 0px; border: 0px; position: relative; text-align: center; font-size: 12px; line-height: 16px; color: rgb(153, 153, 153);">图 | 良渚实验室（来源：http://dwz.date/eXjw）</p></div><p data-track="119" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">夏宏光从事“选择性自噬” 研究逾十五年，师从美国科学院院士袁钧瑛教授和中国科学院院士马大为教授。他和马大为院士合作开发的第三代 EGFR（自噬上游调控蛋白）有机小分子抑制剂 ES-072，已获美国临床批和中国 1.1 类新药临床批件，且已初步完成临床 I 期实验。</span></span></p><p data-track="120" class="syl-page-br" style="margin-top: 18px; margin-bottom: 18px; padding: 0px; border: 0px; height: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><br></p><p data-track="121" style="margin-top: 20px; margin-bottom: 20px; padding: 0px; border: 0px; color: rgb(34, 34, 34); font-family: "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei", "WenQuanYi Micro Hei", "Helvetica Neue", Arial, sans-serif; font-size: 16px; text-align: start; white-space: normal;"><span style="margin: 0px; padding: 0px; border: 0px; letter-spacing: 1px;"><span style="margin: 0px; padding: 0px; border: 0px; color: rgb(89, 89, 89); --tt-darkmode-color: #595959;">谈及未来，他说，“希望所在团队成为全球选择性自噬药物开发的领跑者。”</span></span></p>  
</div>
            